Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fiserv, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Clover platform and its impact on merchant business [1][3]. Group 1: Allegations Against Fiserv - The complaint alleges that Fiserv forced merchants using its older Payeezy platform to switch to the Clover platform due to cost issues and other problems [3]. - It is claimed that Clover's revenue growth was artificially inflated by these conversions, masking a slowdown in acquiring new merchants [3]. - Following the conversions, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and inadequate customer service [3]. - As a result of these merchant losses, Clover's growth in Gross Payment Volume (GPV) and revenue was said to be unsustainable and significantly slowing [3]. - The lawsuit asserts that Fiserv's positive statements regarding Clover's growth strategies and business prospects were materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as July 24, 2024, to July 22, 2025 [3]. - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially be appointed as lead plaintiffs [4]. - There is no cost or obligation for shareholders to participate in the case, and they will receive updates through a portfolio monitoring software [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Snap Inc. regarding a class action lawsuit due to misleading statements about the company's advertising revenue growth, which significantly declined during the reported period [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from April 29, 2025, to August 5, 2025 [3]. - Allegations include that Snap's management provided overly positive statements while concealing a significant decline in advertising revenue growth, which dropped from 9% in Q1 to only 1% in April 2025 [3]. Financial Impact - On August 5, 2025, Snap announced a slowdown in advertising revenue growth, attributing it to issues with their ad platform and external factors [3]. - Following this announcement, Snap's stock price fell from $9.39 per share to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by October 20, 2025, to potentially be appointed as lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - The complaint against LifeMD alleges that the company and its executives violated federal securities laws by making misleading statements and failing to disclose critical information regarding their competitive position and customer acquisition costs [2]. Financial Performance - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from the previous guidance of $268 to $275 million [3]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [3]. Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4]. - The law firm Faruqi & Faruqi encourages individuals with information regarding LifeMD's conduct to come forward, including whistleblowers and former employees [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. due to allegations of violations of federal securities laws and unlawful business practices following a negative report on its product Vykat XR [2][3]. Group 1: Company Overview - Soleno Therapeutics, Inc. (NASDAQ: SLNO) is facing scrutiny after a report from Scorpion Capital labeled its only product, Vykat XR, as overpriced and potentially unsafe for children [3]. - Following the report's publication on August 15, 2025, Soleno's stock price dropped by $5.73 per share, representing a decline of 7.41%, closing at $71.63 per share [3]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is encouraging investors who suffered losses from Soleno's stock to contact them to discuss their legal rights and options [1][4]. - The law firm is specifically looking into whether Soleno has engaged in unlawful business practices that could have harmed investors [2].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices, following a significant drop in stock price after the announcement of clinical trial results for Hyalofast [1][3]. Group 1: Company Overview - Anika Therapeutics, Inc. (NASDAQ: ANIK) is involved in the development of medical products, including Hyalofast, a resorbable hyaluronic acid scaffold for cartilage repair [3]. - The company recently announced topline results from a pivotal clinical trial, which indicated that while Hyalofast showed improvements in treated patients, it did not meet its pre-specified co-primary endpoints [3]. Group 2: Stock Performance - Following the announcement of the clinical trial results, Anika's stock price fell by $3.06 per share, representing a decline of 27.42%, closing at $8.10 per share on July 30, 2025 [3]. Group 3: Legal Investigation - Bragar Eagel & Squire, P.C. is encouraging investors who suffered losses due to the stock price decline to contact them to discuss their legal rights and options [1][4]. - The investigation is focused on whether Anika's actions may have constituted violations of federal securities laws [1].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of CTO Realty Growth, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its dividends and financial practices during the specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint claims that CTO Realty Growth, Inc. misled investors by stating that its dividends were sustainable, while in reality, they were less sustainable than represented [1] - It is alleged that the company used deceptive practices to inflate its adjusted funds from operations and overstate the profitability of its Ashford Lane property [1] - Consequently, the business and financial prospects of CTO were overstated, leading to materially false and misleading public statements [1] Class Period and Registration - The class period for the allegations spans from February 18, 2021, to June 24, 2025 [1] - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for October 7, 2025 [2] Firm's Commitment - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to ensure companies adhere to responsible business practices [3]

Group 1 - The law firm Kirby McInerney LLP is investigating potential claims against National Grid USA Service Company, Inc. for possible violations of federal securities laws and unlawful business practices [1] - A report by the National Energy System Operator revealed that a fire at Heathrow Airport was caused by a known fault at an electrical substation owned by National Grid, which the company had been aware of since 2018 but failed to address [3] - Following the release of the NESO report, National Grid's American Depositary Receipt (ADR) price fell by $3.77, or approximately 5.07%, from $74.38 to $70.61 [3] Group 2 - Kirby McInerney LLP specializes in securities litigation and has achieved recoveries totaling billions of dollars for shareholders [6]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to enhance its market reach and sales [2][3]. Group 2: Financial Reporting Issues - The company claimed that the integration of Pro-ficiency would double its total addressable market and significantly contribute to sales, but it appears that the integration was not successful and internal controls were ineffective [3]. - On April 15, 2025, Simulations Plus appointed Grant Thornton LLP as its new auditor, but shortly after, it reported disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties [4]. Group 3: Stock Performance - Following the announcement of disappointing financial results on June 11, 2025, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - On July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, which raised concerns about its internal controls and financial reporting [5]. - The stock price fell again by $4.50, nearly 26%, from $17.47 to $12.97 per share after the news of the impairment charge and auditor dismissal [5].

Core Viewpoint - Centene Corporation experienced a significant decline in stock price following the release of disappointing Q2 2025 financial results, leading to a class action lawsuit from investors alleging misleading statements about the company's financial health and market conditions [1][2][4]. Financial Performance - Centene reported a GAAP diluted loss per share of -$0.51 for Q2 2025, primarily due to a reduction in the company's net 2025 Marketplace risk adjustment revenue transfer estimate [4]. - The company withdrew its 2025 financial guidance on July 1, 2025, after a review revealed lower-than-expected market growth and higher morbidity levels than previously assumed, resulting in a stock price drop of over 40% [6]. Legal Issues - A class action lawsuit, Lunstrum v. Centene Corporation, has been filed, representing investors who acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [2][4]. - The lawsuit claims that Centene's leadership misled investors by presenting an overly optimistic view of the company's financial health, despite internal data indicating lower enrollment and higher morbidity rates [5][7]. Market Conditions - Centene's public statements had previously suggested expanding market share and robust business performance, particularly in serving underinsured and uninsured populations, which the lawsuit argues were not aligned with actual operational metrics [5][7]. - A preliminary analysis indicated that more than two-thirds of Centene's Marketplace share showed lower-than-expected enrollment, contradicting the company's optimistic reports [5].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against PubMatic, Inc. for possible violations of federal securities laws and unlawful business practices [2] - PubMatic reported a significant revenue decline expected in Q3 2025 due to reduced ad spending from a major demand-side platform (DSP) partner, leading to a 21.1% drop in share price [3] Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in PubMatic to contact them to discuss their legal rights [1][4] - The investigation focuses on whether PubMatic has engaged in unlawful business practices that may have affected stockholder interests [2] Group 2: Financial Performance - PubMatic's Q2 2025 financial report indicated a headwind from a top DSP buyer, which has shifted clients to a new platform [3] - Following the announcement, PubMatic's share price fell from $10.57 to $8.34, a decrease of $2.23 per share [3]